Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial

Currently, a standard therapy has not been established for recurrent or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. While there are many treatment options, such as hematopoietic stem cell transplantation, patients with resistant disease to conventional chemotherapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Hirokazu, Fukano, Reiji, Sekimizu, Masahiro, Kada, Akiko, M. Saito, Akiko, Asada, Ryuta, Mori, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2017
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577026/
https://www.ncbi.nlm.nih.gov/pubmed/28878445
http://dx.doi.org/10.18999/nagjms.79.3.407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577026/
https://www.ncbi.nlm.nih.gov/pubmed/28878445
http://dx.doi.org/10.18999/nagjms.79.3.407

Ejemplares similares